# Treatment options for alpha-1 antitrypsin deficiency
Treatment of alpha-1 antitrypsin deficiency (AATD) focuses on two important goals: slowing lung damage and preventing or relieving liver disease. Because the disease is incurable, treatment is mainly about stabilizing the condition and reducing symptoms. Treatment varies considerably depending on the severity of lung damage and liver disease at the time of diagnosis, and is adjusted over time as the disease progresses.
Alpha-1 antitrypsin replacement (protease inhibitor)
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is the only specific treatment targeting the underlying defect and is administered intravenously. It contains active alpha-1 antitrypsin that enters the bloodstream directly and protects lung tissue against enzymes released by inflammatory cells.
*How it works*
The administered protease inhibitor (also called intravenous augmentation therapy) raises the level of active alpha-1 antitrypsin in the blood above a certain threshold, which can slow damage to lung tissues. Studies show that in particular for people with severe lung damage (reduced lung function), this can slow the decline.
*Side effects*
Overall, the treatment is well tolerated. Previously, infectious complications were a risk because the product came from human blood plasma, but modern production methods have significantly reduced this risk. Inflammatory reactions to the infusion itself are rare but can occur. Patients and their doctors regularly discuss how long the infusion takes and how frequently it is given.
Inhalation therapy with local antiprotease agents
ResearchediPositive results in clinical studies, not yet standard treatment
In addition to the intravenous approach, research is being conducted into whether antiprotease agents can be delivered directly into the lung via inhalation. This could work locally in lung tissue without burdening the whole body.
*How it works*
When antiprotease agents reach the lung directly through nebulization or inhaler, they can locally inhibit inflammatory enzymes and prevent damage. Preliminary results are encouraging, but the treatment is not yet on the standard list in all countries.
*Side effects*
Because the drug acts locally, systemic side effects are unlikely. Local irritation of the airways can occur, and like other inhalation therapies, some people may experience coughing or shortness of breath.
Treatment of lung disease: maintaining lung function
Quitting smoking and air quality
ProveniIncluded in official guidelines, or approved by EMA or FDA
Smoking drastically accelerates lung damage and is the most powerful modifiable risk factor. Exposure to occupational dust and air pollution should also be limited as much as possible.
*Why this works*
Smoke causes extra inflammation in the lungs and also attracts more inflammatory cells. In people with AATD, this significantly accelerates the breakdown of lung tissue. Quitting smoking can noticeably slow the rate of decline, even when the disease is already established.
Physiotherapy and exercise
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular physical activity, adapted to the patient's abilities, helps maintain lung function longer and supports overall well-being.
*How it works*
Exercise supports muscle strength, promotes exhalation, and can reduce inflammation in the body. Many patients perform breathing exercises and receive advice from respiratory physiotherapists on how the body can function more efficiently despite reduced lung capacity.
Treatment of complications: airway obstruction
ProveniIncluded in official guidelines, or approved by EMA or FDA
When airway narrowing occurs (due to chronic obstructive pulmonary disease, COPD), bronchodilating medications can be used.
*How it works*
These medications relax the smooth muscles around the airways so air flows more easily. They reduce shortness of breath and can be administered via inhaler or as a tablet. These are the same medications used for COPD from other causes.
*Side effects*
Tremor, palpitations, and sleep disturbances may occur, depending on the specific medication. The doctor discusses with the patient which medication is best suited.
Treatment of exacerbations (acute worsening)
ProveniIncluded in official guidelines, or approved by EMA or FDA
When infections or sudden inflammatory flares occur, antibiotics, corticosteroids, and extra pulmonary physiotherapy may be needed to achieve stabilization.
*How it works*
Antibiotics combat bacterial superinfections. Corticosteroids suppress the inflammatory response. Intensive care helps the body return to its previous baseline. Patients often learn to recognize early warning signs so they can intervene more quickly.
Treatment of liver disease
Surveillance and screening
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular monitoring of liver function and structural changes is standard, even in patients who initially have no symptoms.
*How it works*
Through blood tests and periodic imaging (ultrasound or elastography), it is monitored whether and how quickly liver disease develops. Early detection of cirrhosis or rising portal pressure makes early intervention possible. This applies especially to carriers of the homozygous Pi*ZZ genotype deficiency.
Portal hypertension and cirrhosis: supportive care
ProveniIncluded in official guidelines, or approved by EMA or FDA
When the liver becomes diseased, complications such as portal hypertension (elevated blood pressure in the liver circulation) may occur.
*How it works*
Depending on severity, varices (dilated veins in the esophagus and stomach) are screened for and prevented. Ascites (fluid in the abdomen) can be managed with diet and fluid and salt restriction or diuretics. For advanced cirrhosis, liver transplantation may ultimately be the only option.
*Side effects*
Medications for portal hypertension can cause dizziness, fatigue, and electrolyte disturbances. The doctor monitors these effects closely.
Screening and prevention in children
ProveniIncluded in official guidelines, or approved by EMA or FDA
Newborns with AATD are screened for congenital liver disease (neonatal cholestatic hepatitis and biliary atresia) and receive early care.
*How it works*
Early diagnosis and monitoring strategy help prevent or detect severe liver damage in very young children early. Some children will not develop symptoms, others will have signs of cholestasis (bile stasis); close monitoring determines the further course.
Antithrombotic agents and liver policy
ResearchediPositive results in clinical studies, not yet standard treatment
Research is underway into medications that counter the abnormal accumulation of alpha-1-antitrypsin in the liver, so that proteotoxicity (toxic protein accumulation) is reduced.
*How it works*
This approach focuses on breaking down or mobilizing misfolded proteins in liver cells, thereby reducing the toxicity of internal accumulation. To date, these are mainly experimental approaches in laboratories and early clinical studies.
Gene therapy and gene editing
ExperimentaliOngoing in study setting, outcome still unknown
Research into direct correction of the defective SERPINA1 gene (via CRISPR and other techniques) and regeneration of protein production is ongoing from time to time.
*How it works*
These approaches would address the lack of functional protein at its source. CRISPR gene editing and base editing could in theory correct mutations. Currently, such treatments are still in preclinical and early clinical research phases.
*Status*
This is an active research area with progress, especially in rare genetic liver disease. Patients can find information about ongoing trials via clinics or patient organizations.
Supportive measures
Vaccination
ProveniIncluded in official guidelines, or approved by EMA or FDA
Being vaccinated against influenza, pneumococci, and other respiratory infections is important because lung infections can lead to sudden deterioration.
Monitoring and multidisciplinary care
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular contact with specialists (pulmonologist, hepatologist, physiotherapist) enables coordination and ensures that newer insights can be quickly implemented.
Lifestyle: diet and weight
ProveniIncluded in official guidelines, or approved by EMA or FDA
A healthy body weight and nutrition that counteracts inflammation support the body in coping with chronic damage.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._